Form 4: Director Luke Evnin Sells 76,928 Shares of HOWL

Director Luke Evnin of Werewolf Therapeutics, Inc. reported the sale of 76,928 shares of common stock via a Rule 10b5-1 trading plan.

Summary

• Director Luke Evnin sold 76,928 shares of Werewolf Therapeutics, Inc. (HOWL) common stock on June 9, 2026.
• The shares were sold at a weighted average price of $0.37 per share, with individual transaction prices ranging from $0.3553 to $0.3851.
• The sale was executed pursuant to a Rule 10b5-1 trading plan established on March 26, 2026.
• Following the transaction, the reporting person maintains an indirect beneficial ownership of 300,283 shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event; while insider selling is generally viewed with caution, the use of a pre-established 10b5-1 plan suggests a routine financial move rather than a reaction to negative news.

Positives

• The transaction was pre-planned under a Rule 10b5-1 trading plan, which is a standard mechanism for insiders to sell shares without concerns regarding non-public information.

Negatives

• The sale represents a divestment of equity by a company director, which may be perceived as a lack of confidence in the short-term share price performance.

Risks

• The stock is currently trading at a low valuation (sub-$0.40 range), which may indicate ongoing financial or operational challenges for the company.

Future Outlook

No specific forward-looking guidance regarding company operations was provided in this filing.

Industry Context

StockSavvy.ai notes that insider selling in micro-cap biotech firms is common for liquidity purposes, particularly when trading plans are utilized to mitigate regulatory scrutiny.

Comparison to Industry Standards

• The use of Rule 10b5-1 plans is the industry standard for corporate insiders to conduct orderly divestments.
• The low share price reflects the high-risk nature of early-stage clinical biotech companies.

Related Party Transactions

• The shares were sold by various MPM-affiliated entities, including MPM Asset Management LLC and MPM BioVentures 2014, L.P., for which Luke Evnin serves as a manager or director.

Stakeholder Impact

• Shareholders may view the director's divestment as a signal of limited near-term upside, though the volume is relatively small compared to total outstanding shares.

Next Steps

• Continued monitoring of future Form 4 filings for further insider activity.

Key Dates

Keywords

Werewolf Therapeutics, HOWL, Insider Trading, Form 4, Biotech, Luke Evnin